Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.
Pharma & Biotech
Pharma & Biotech
Oral complement therapy for myasthenia gravis? Novartis’ iptacopan enters the neurology arena
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.